Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Tobramycin in Preterm Infants With BPD
NCT04560179Phase 1Completed
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tobramycin in bronchopulmonary dysplasia (BPD) (5 arms). Primary endpoint: Elevated Serum Tobramycin Trough or Creatinine or Severe Adverse Event at 14 days. Started Mar 2022; status: completed.
02
Drugs
tobramycin
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT04560179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560179.